- Home
- Companies
- canada quebec
- drug use
Refine by
Drug Use Technology Serving Quebec
11 companies found
Technologybased inParis, FRANCE
CHROMagar™ was incorporated in 1993 by the inventor, and pioneer in chromogenic culture media technology, Dr Alain Rambach. Established in the heart of Paris (France) close to the famous Pasteur Institute where Dr Rambach began his research career, ...
Performance: β-Lactamase production (ESBL, AmpC, carbapenemase) is the most common mechanism of β-lactam drug resistance in Gram negative bacteria. Each of the involved mechanisms can be plasmid-encoded and transfer horizontally. Moreover, ...
Technologybased inCarmel, INDIANA (USA)
Sword Diagnostics is a cutting-edge life sciences company created in response to the rapidly evolving needs of the research and pharmaceutical communities. Although researchers are discovering thousands of biomarkers associated with both healthy and ...
Not for medical diagnostic use. For in vitro use only. By use of this product, recipient agrees to be bound by the terms of this limited use statement. If the recipient is not willing to accept the conditions of this limited use statement, and the ...
Technologybased inBundoora, AUSTRALIA
AdAlta is an innovative, clinical stage biotech company developing a unique range of new drug treatments. AdAlta has pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, discovered initially in sharks and ...
An i-body is a human protein that belongs to the class of next generation antibodies. The i-body is built on the scaffold of a human protein and engineered with two loops that mimic the shape of shark antibodies. These loops are responsible for ...
Technologybased inCoral Gables, FLORIDA (USA)
We are a late-stage biotech company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their ...
Novel MOA: REL-1017 works as an NMDAR channel blocker with preferential activity at hyperactive GluN1-GluN2D channels. REL-1017 is a novel N-methyl-D-aspartate receptor (NMDAR) channel blocker in phase 3 clinical trials for the treatment of Major ...
Technologybased inHamburg, GERMANY
Revvity Gene Delivery (formerly SIRION Biotech) supports your cell and gene therapy development process ̶ offering solutions for early R&D all the way to clinical applications, with easy transfer of processes and assays into GMP production. ...
Technologybased inCambridge, UNITED KINGDOM
We’re driven by the shared purpose of breaking new ground in the discovery of new treatments for rare diseases. Healx is a mission-driven technology company pioneering the next wave of drug discovery in order to bring novel, effective treatments to ...
Technologybased inMilan, ITALY
Italfarmaco SpA is a private Italian multinational company located in Milan, operating in Italy and abroad in both the pharmaceutical and fine chemical industries through its controlled and/or participated companies. Italfarmaco was establish in ...
Italfarmaco is a concrete reality in the Italian pharmaceutical industry; it has been active in pharmaceutical research and development ...
Technologybased inDavis, CALIFORNIA (USA)
Headquartered in Davis, California, Expression Systems is dedicated to supplying and servicing the baculovirus, cell culture and bio-industrial markets with innovative media formulations, complementary products and contract services. We specialize ...
Technologybased inSaint Paul, MINNESOTA (USA)
Innovation Focused on Improving Patient Care: Manufactured from our pharmaceutical grade of NOCC chitosan polymer technology, the PosiSep® X hemostat dressing/intranasal splint provides both superior performance and patient comfort. There is really ...
Technologybased inKiel, GERMANY
tiakis biotech AG (“tiakis”) – formerly Proteo Biotech AG - is the next generation preventive therapeutic technology company. We focus on our clinical-stage proprietary and pioneering tissue protective drug ...
Technologybased inVancouver, BRITISH COLUMBIA (CANADA)
Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of ...
ZW49 is a HER2-targeted antibody drug conjugate (ADC) developed using Zymeworks’ proprietary Azymetric™ and ZymeLink™ platforms. ZW49 is currently being evaluated in a Phase 1 clinical trial as a ...